Our Programs
At AlgorithmicRx, we are building a pipeline of AI-powered therapies to address some of the most pressing unmet needs in rare disease drug development. We begin our journey with Duchenne Muscular Dystrophy (DMD) and will expand our focus to other muscular dystrophies and ultimately, a broader range of rare diseases where patients have limited or no treatment options.
Duchenne Muscular Dystrophy
-
To date, 8 therapies have been approved for DMD.
-
Some are mutation-specific, meaning they only help a subset of patients.
-
A few are effective in younger, ambulatory patients, but come with high market costs and limited accessibility.
Despite these advancements, there remains a significant unmet need for older and non-ambulatory patients, who are often left without effective treatment options.
At AlgorithmicRx, our focus is on developing oral small-molecule therapies that are disease-modifying in nature—bringing scalable, accessible, and meaningful solutions to patients who need them the most.
Orphan drugs: cures for the overlooked
-
Turning rare challenges into breakthrough therapies.
Other Muscular Dystrophies
-
Expanding learnings from DMD
-
Targeting scalable therapies for broader patient groups
Other Rare Diseases
-
Applying our AI-driven platform to multiple indications
-
Delivering accessible, patient-centered treatments
By starting with DMD, we aim to prove that AI-powered drug development can overcome the long-standing challenges of rare diseases. Our vision is to expand these breakthroughs across muscular dystrophies and ultimately, to rare diseases of all kinds—bringing hope, health, and cures to patients who have been waiting far too long.